BioAlliance Pharma files Loramyc in the US for candidiasis
This article was originally published in Scrip
Executive Summary
BioAlliance Pharma SA has submitted an NDA to the US FDA for its antifungal Loramyc (miconazole Lauriad) mucoadhesive buccal tablets for the treatment of oropharyngeal candidiasis in immunocompromised patients.